Literature DB >> 10981553

Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential hypertension in whites and African Americans.

V Herrmann1, R Büscher, M M Go, K M Ring, J K Hofer, M T Kailasam, D T O'Connor, R J Parmer, P A Insel.   

Abstract

Beta2-adrenergic receptors (beta2-AR) contribute to cardiovascular regulation by influencing several functions and previous studies suggest that a decreased function of the beta2-AR may be involved in essential hypertension. Beta2-AR are polymorphic and certain polymorphisms of these receptors are of functional importance. We focus here on the Arg16-->Gly16 beta2-AR polymorphism, which shows enhanced agonist-promoted downregulation of the receptor and which, in two recent studies, yielded opposite results in terms of association with essential hypertension: an increased frequency of the Gly16 variant in African-Caribbean hypertensives and of the Arg16 variant in offspring of Norwegian white hypertensive parents. In the current study, we genotyped 243 subjects, including both African-American and white individuals, for codon 16 polymorphism and assessed blood pressure and cardiovascular function using impedance cardiography and pressor sensitivity to phenylephrine. We found similar patterns of cardiovascular function and expression of hypertension with the two genotypes of codon 16. There was no statistically significant difference in the overall allelic distribution of the two genotypes: among African-Americans, 51% of the hypertensives and 50% of the normotensives carried the Arg16 allele, whereas among the white subjects 40% of the hypertensives and 47% of the normotensives were carriers of the Arg16 allele. Although we observed a statistically significant increase in the Arg16/Gly16 heterozygotes in the African-American population, the Gly16 allele was not significantly increased in the African-Americans compared to whites. These findings indicate that the codon 16 polymorphisms are not associated with hypertension in a mixed American study population nor do they appear to substantially impact on a variety of hemodynamic variables.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981553     DOI: 10.1016/s0895-7061(00)01188-2

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

1.  Common genetic variation in the 3'-untranslated region of gonadotropin-releasing hormone receptor regulates gene expression in cella and is associated with thyroid function, insulin secretion as well as insulin sensitivity in polycystic ovary syndrome patients.

Authors:  Qiaoli Li; Guizhong Yang; Ying Wang; Xiaoping Zhang; Qing Sang; Huan Wang; Xinzhi Zhao; Qinghe Xing; Lin He; Lei Wang
Journal:  Hum Genet       Date:  2011-01-28       Impact factor: 4.132

Review 2.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

3.  Synopsis and data synthesis of genetic association studies in hypertension for the adrenergic receptor family genes: the CUMAGAS-HYPERT database.

Authors:  Georgios D Kitsios; Elias Zintzaras
Journal:  Am J Hypertens       Date:  2009-12-31       Impact factor: 2.689

Review 4.  Neurogenic hypertension: pathophysiology, diagnosis and management.

Authors:  Samuel J Mann
Journal:  Clin Auton Res       Date:  2018-07-04       Impact factor: 4.435

5.  Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk.

Authors:  Lian Zhang; Fangwen Rao; Kuixing Zhang; Srikrishna Khandrika; Madhusudan Das; Sucheta M Vaingankar; Xuping Bao; Brinda K Rana; Douglas W Smith; Jennifer Wessel; Rany M Salem; Juan L Rodriguez-Flores; Sushil K Mahata; Nicholas J Schork; Michael G Ziegler; Daniel T O'Connor
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Neuropeptide Y(1) Receptor NPY1R discovery of naturally occurring human genetic variants governing gene expression in cella as well as pleiotropic effects on autonomic activity and blood pressure in vivo.

Authors:  Lei Wang; Fangwen Rao; Kuixing Zhang; Manjula Mahata; Juan L Rodriguez-Flores; Maple M Fung; Jill Waalen; Myles G Cockburn; Bruce A Hamilton; Sushil K Mahata; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

7.  Common genetic variants in the chromogranin A promoter alter autonomic activity and blood pressure.

Authors:  Y Chen; F Rao; J L Rodriguez-Flores; N R Mahapatra; M Mahata; G Wen; R M Salem; P-A B Shih; M Das; N J Schork; M G Ziegler; B A Hamilton; S K Mahata; D T O'Connor
Journal:  Kidney Int       Date:  2008-04-23       Impact factor: 10.612

8.  Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion.

Authors:  Yuqing Chen; Fangwen Rao; Juan L Rodriguez-Flores; Manjula Mahata; Maple M Fung; Mats Stridsberg; Sucheta M Vaingankar; Gen Wen; Rany M Salem; Madhusudan Das; Myles G Cockburn; Nicholas J Schork; Michael G Ziegler; Bruce A Hamilton; Sushil K Mahata; Laurent Taupenot; Daniel T O'Connor
Journal:  J Am Coll Cardiol       Date:  2008-10-28       Impact factor: 24.094

9.  Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology.

Authors:  Gen Wen; Sushil K Mahata; Peter Cadman; Manjula Mahata; Sajalendu Ghosh; Nitish R Mahapatra; Fangwen Rao; Mats Stridsberg; Douglas W Smith; Payam Mahboubi; Nicholas J Schork; Daniel T O'Connor; Bruce A Hamilton
Journal:  Am J Hum Genet       Date:  2004-01-12       Impact factor: 11.025

10.  In-vitro relationship between protein-binding and free drug concentrations of a water-soluble selective beta-adrenoreceptor antagonist (atenolol) and its interaction with arsenic.

Authors:  M A Alam; M A Awal; N Subhan; M Mostofa
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.